These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18337095)

  • 1. Aryl-indolyl maleimides as inhibitors of CaMKIIdelta. Part 3: Importance of the indole orientation.
    Lu Q; Chen Z; Perumattam J; Wang DX; Liang W; Xu YJ; Do S; Bonaga L; Higaki J; Dong H; Liclican A; Sideris S; Laney M; Dugar S; Mavunkel B; Levy DE
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2399-403. PubMed ID: 18337095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aryl-indolyl maleimides as inhibitors of CaMKIIdelta. Part 2: SAR of the amine tether.
    Levy DE; Wang DX; Lu Q; Chen Z; Perumattam J; Xu YJ; Higaki J; Dong H; Liclican A; Laney M; Mavunkel B; Dugar S
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2395-8. PubMed ID: 18334295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aryl-indolyl maleimides as inhibitors of CaMKIIdelta. Part 1: SAR of the aryl region.
    Levy DE; Wang DX; Lu Q; Chen Z; Perumattam J; Xu YJ; Liclican A; Higaki J; Dong H; Laney M; Mavunkel B; Dugar S
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2390-4. PubMed ID: 18334294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrimidine-based inhibitors of CaMKIIdelta.
    Mavunkel B; Xu YJ; Goyal B; Lim D; Lu Q; Chen Z; Wang DX; Higaki J; Chakraborty I; Liclican A; Sideris S; Laney M; Delling U; Catalano R; Higgins LS; Wang H; Wang J; Feng Y; Dugar S; Levy DE
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2404-8. PubMed ID: 18334293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors.
    Peifer C; Stoiber T; Unger E; Totzke F; Schächtele C; Marmé D; Brenk R; Klebe G; Schollmeyer D; Dannhardt G
    J Med Chem; 2006 Feb; 49(4):1271-81. PubMed ID: 16480264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of novel 7-azaindazolyl-indolyl-maleimide derivatives as antitumor agents and protein kinase C inhibitors.
    Ye Q; Cao J; Zhou X; Lv D; He Q; Yang B; Hu Y
    Bioorg Med Chem; 2009 Jul; 17(13):4763-72. PubMed ID: 19447039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
    Sawyer JS; Anderson BD; Beight DW; Campbell RM; Jones ML; Herron DK; Lampe JW; McCowan JR; McMillen WT; Mort N; Parsons S; Smith EC; Vieth M; Weir LC; Yan L; Zhang F; Yingling JM
    J Med Chem; 2003 Sep; 46(19):3953-6. PubMed ID: 12954047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibacterial activity of a novel series of 3-bromo-4-(1H-3-indolyl)-2,5-dihydro-1H-2,5-pyrroledione derivatives--an extended structure-activity relationship study.
    Mahboobi S; Eichhorn E; Winkler M; Sellmer A; Möllmann U
    Eur J Med Chem; 2008 Mar; 43(3):633-56. PubMed ID: 17624634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-Phenyl-7-azaindoles as potent and selective IKK2 inhibitors.
    Liddle J; Bamborough P; Barker MD; Campos S; Cousins RP; Cutler GJ; Hobbs H; Holmes DS; Ioannou C; Mellor GW; Morse MA; Payne JJ; Pritchard JM; Smith KJ; Tape DT; Whitworth C; Williamson RA
    Bioorg Med Chem Lett; 2009 May; 19(9):2504-8. PubMed ID: 19349179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors.
    Liu X; Hu Y; Gao A; Xu M; Gao L; Xu L; Zhou Y; Gao J; Ye Q; Li J
    Bioorg Med Chem; 2019 Feb; 27(4):589-603. PubMed ID: 30600148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure and activity relationship of 2-(substituted benzoyl)-hydroxyindoles as novel CaMKII inhibitors.
    Komiya M; Asano S; Koike N; Koga E; Igarashi J; Nakatani S; Isobe Y
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1456-8. PubMed ID: 21292482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3.
    Zhang HC; Boñaga LV; Ye H; Derian CK; Damiano BP; Maryanoff BE
    Bioorg Med Chem Lett; 2007 May; 17(10):2863-8. PubMed ID: 17350261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of peptidic maleimides as transglutaminase inhibitors.
    Halim D; Caron K; Keillor JW
    Bioorg Med Chem Lett; 2007 Jan; 17(2):305-8. PubMed ID: 17092716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell biology. Lessons in rational drug design for protein kinases.
    Ahn NG; Resing KA
    Science; 2005 May; 308(5726):1266-7. PubMed ID: 15919981
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of hydrogen peroxide-induced necrotic cell death with 3-amino-2-indolylmaleimide derivatives.
    Dodo K; Katoh M; Shimizu T; Takahashi M; Sodeoka M
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3114-8. PubMed ID: 15878276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-chloroindole-7-yl-based factor Xa inhibitors.
    Shi Y; Sitkoff D; Zhang J; Klei HE; Kish K; Liu EC; Hartl KS; Seiler SM; Chang M; Huang C; Youssef S; Steinbacher TE; Schumacher WA; Grazier N; Pudzianowski A; Apedo A; Discenza L; Yanchunas J; Stein PD; Atwal KS
    J Med Chem; 2008 Dec; 51(23):7541-51. PubMed ID: 18998662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, syntheses, biological evaluation, and docking studies of 2-substituted 5-methylsulfonyl-1-phenyl-1H-indoles: potent and selective in vitro cyclooxygenase-2 inhibitors.
    Cruz-López O; Díaz-Mochón JJ; Campos JM; Entrena A; Núñez MT; Labeaga L; Orjales A; Gallo MA; Espinosa A
    ChemMedChem; 2007 Jan; 2(1):88-100. PubMed ID: 17131462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the ATP binding sites of protein kinases using conformationally diverse bisindolylmaleimides.
    Bartlett S; Beddard GS; Jackson RM; Kayser V; Kilner C; Leach A; Nelson A; Oledzki PR; Parker P; Reid GD; Warriner SL
    J Am Chem Soc; 2005 Aug; 127(33):11699-708. PubMed ID: 16104747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
    Schirok H; Kast R; Figueroa-Pérez S; Bennabi S; Gnoth MJ; Feurer A; Heckroth H; Thutewohl M; Paulsen H; Knorr A; Hütter J; Lobell M; Münter K; Geiss V; Ehmke H; Lang D; Radtke M; Mittendorf J; Stasch JP
    ChemMedChem; 2008 Dec; 3(12):1893-904. PubMed ID: 18973168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-(7-Azaindolyl)-4-indolylmaleimides as a novel class of mutant isocitrate dehydrogenase-1 inhibitors: Design, synthesis, and biological evaluation.
    Hu Y; Gao A; Liao H; Zhang M; Xu G; Gao L; Xu L; Zhou Y; Gao J; Ye Q; Li J
    Arch Pharm (Weinheim); 2018 Oct; 351(10):e1800039. PubMed ID: 30113716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.